Phase II, epidemiologic, open-label study of eculizumab in patients with Shiga-toxin producing E. coli haemolytic uraemic syndrome (STEC-HUS)

Trial Profile

Phase II, epidemiologic, open-label study of eculizumab in patients with Shiga-toxin producing E. coli haemolytic uraemic syndrome (STEC-HUS)

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2013

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome; Shiga-toxigenic Escherichia coli infections
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2013 New trial record
    • 24 Oct 2013 Alexion Pharmaceuticals continues to analyse longer-term control clinical outcome data from this study, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top